Sun Pharma Advanced Research Company credit ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
55655625847.075.0
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
555555256−110−327
0.42×0.42×−1.19×0.37×0.15×
0.41×0.41×−1.18×−0.88×−0.64×
0.35×0.35×−0.80×−0.12×—
0.34×0.35×−0.79×0.27×—
46.54×46.54×−37.12×−245.33×—
29.3%29.3%626.1%27.2%12.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SPARC₹182.98

Sun Pharma Advanced Research Company Ltd.

· Pharma & Health
₹ CrorePeersSTARSHILPAMEDSUPRIYATHYROCARERUBICONVIYASHYATHARTHPARKHOSPSMcap ₹5,938 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt75.047.0258.2556.1556.1
Net Debt-327.5-110.1256.2555.0555.0
Total Debt/Equity0.150.37-1.190.420.42
Net Debt/Equity-0.64-0.88-1.180.410.41
Total Debt/EBITDA—-0.12-0.800.350.35
Net Debt/EBITDA—0.27-0.790.350.34
Interest Coverage (EBIT/Interest)—-245.33-37.1246.5446.54
Total Debt/Total Capital %12.7627.21626.0729.3529.35
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.